genie app

Oscar-winning director Christopher Nolan will be taking audiences to mythical Greece with his latest project. Universal Pictures announced this week that Nolan will be directing a cinematic adaptation of " The Odyssey ," an ancient poem believed to be written by Homer between 750 and 650 BCE centering on the character Odysseus' 10-year trek home after the Trojan War. Nolan's forthcoming adaptation is described as "a mythic action epic shot across the world using brand new IMAX film technology," according to the studio's announcement posted to their X page Monday. Zendaya, Tom Holland and Robert Pattinson along with Oscar-winners Matt Damon, Lupita Nyong'o, Anne Hathaway and Charlize Theron are reportedly set to star in the film. Holland recently spoke about signing onto the project, saying on "The Dish" podcast last week that the film hasn't started shooting yet. He added that Nolan only "loosely pitched" it to him when they met to discuss the project, but that he still didn't know all the details. The "Spider-Man" actor also touched on working with his girlfriend Zendaya, joking that "studios love it" when they're on the same project because they only have to pay for "one hotel room." Pattinson, Damon and Hathaway have all previously appeared in Nolan's films, including "Tenet," "Interstellar" and "Oppenheimer." Nolan is also behind epic films including "Inception," "The Dark Knight," "Dunkirk" and his most recent film "Oppenheimer," which scored big at last year's Oscars when it took home the trophy for Best Picture. Nolan won that award as a producer and also took home the Academy Award for Best Director. According to Universal's social media announcement this week, "The Odyssey" will bring Homer's "foundational saga to IMAX film screens for the first time" and will open in theaters on July 17, 2026.

— Court Rules in Favor of Heron in Patent Lawsuit Against Fresenius Kabi USA , LLC — SAN DIEGO , Dec. 3, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the U.S. District Court for the District of Delaware ruled in Heron's favor in the Company's patent litigation against Fresenius Kabi USA , LLC with respect to CINVANTI® (aprepitant) injectable emulsion. The district court found that Heron's U.S. Patent Nos. 9,561,229 and 9,974,794, which expire in 2035, are valid and would be infringed by Fresenius' proposed generic product. The district court decision concludes the litigation initiated in July 2022 in response to Fresenius' submission of an Abbreviated New Drug Application with the U.S. Food and Drug Administration seeking approval of a generic version of CINVANTI®. As a result of the decision, Heron will seek an order from the Court prohibiting Fresenius from launching its generic CINVANTI® until after the expiration of the patents in 2035. This decision is subject to appeal. "We are pleased with this anticipated result of the proceeding and will continue to vigorously defend the CINVANTI® patent estate in the future," said Craig Collard, Chief Executive Officer of Heron. "The team at Heron takes great pride in the result of our successful history of developing injectable products, which is demonstrated by the strength of our intellectual property and the performance of our innovative drugs like CINVANTI® in serving patients with serious unmet needs." About Heron Therapeutics, Inc. Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. Our advanced science, patented technologies, and innovative approach to drug discovery and development have allowed us to create and commercialize a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. For more information, visit www.herontx.com . Forward-looking Statements This news release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Heron cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially. Therefore, you should not place undue reliance on forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q, and in our other reports filed with the Securities and Exchange Commission, including under the caption "Risk Factors." Forward-looking statements reflect our analysis only on their stated date, and Heron takes no obligation to update or revise these statements except as may be required by law. Investor Relations and Media Contact: Ira Duarte Executive Vice President, Chief Financial Officer Heron Therapeutics, Inc. iduarte@herontx.com 858-251-4400 View original content to download multimedia: https://www.prnewswire.com/news-releases/us-district-court-upholds-validity-of-cinvanti-patents-302321651.html SOURCE Heron Therapeutics, Inc.By Greg Otto December 4, 2024 A White House official says the Salt Typhoon hack has impacted eight telecom companies in the United States, with dozens of other countries also affected, and has been in motion for as long as two years. The information comes as U.S. administration officials said earlier this week that the hacking group, linked to the Chinese government, is still believed to be in U.S. telecom networks . The government began investigating the breach this past spring, and are continuing to assess its full scope.The spying efforts targeted officials from both presidential campaigns, including the phone of President-elect Donald Trump . Anne Neuberger, the White House’s deputy national security adviser for cyber and emerging technology, said Wednesday the Chinese campaign “has affected dozens of countries around the world.” She also reiterated what other government officials said earlier this week: the attackers are most likely still inside the telecom networks. “There is a risk of ongoing compromises to communications,” Neuberger said. “Until U.S. companies address cybersecurity gaps, the Chinese are likely to maintain their access.” Administration officials did not reveal the full list of companies impacted, nor did they share the countries that may have been affected. However, the White House noted that Chinese cyberespionage efforts have been discovered in the past few years targeting Europe and the Indo-Pacific region. Neuberger said a unified coordination group was established in response to the hack, which meets several times a week. President Joe Biden has been briefed multiple times on the situation. She also emphasized that the targets were among a handful of prominent government and political officials, but the attack “was broad in terms of potential access to communications of everyday Americans.” The White House also believes classified communications were unaffected. The impacted telecommunications companies are currently working to expel the hackers from their networks, but Neuberger said the risk of further breaches remains high until these cybersecurity gaps are fully addressed. The administration has recently convened discussions with telecommunications CEOs and cybersecurity experts to reinforce security measures across the sector. Earlier this week, a host of agencies released communication infrastructure-focused guidance . The agencies responsible were CISA, the National Security Agency, the Federal Bureau of Investigation, the Australian Signals Directorate’s Australian Cyber Security Centre, the Canadian Cyber Security Centre and New Zealand’s National Cyber Security Centre.

Apple again snubs AI in its ‘iPhone App of the Year’ finalistsIsrael launches new strikes on Lebanon as leaders draw closer to ceasefire with Hezbollah